Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 28, 2013

View Archived Issues

High spatio-temporal resolution of broad-spectrum antibacterial activity using light

Nanomerics presents in vivo results for novel nanoparticle LENK formulation

TR-L-382 plus pregabalin shows promise in preclinical models of neuropathic pain

Novel cannabinoid CB2 receptor modulator tested in mice with TBI

Egalet enters abuse-deterrent hydrocodone collaboration with Shionogi

Interleukin Genetics to launch PerioPredict periodontal disease test

Genomic Health licenses Almac technology to develop test to determine chemotherapy benefit

DBV Technologies forms collaboration agreement for whooping cough booster vaccine

ImStar Therapeutics names drug candidate for amyotrophic lateral sclerosis

Novel malaria vaccine from the University of Oxford shows enhanced immunogenicity in vivo

Phase II acromegaly study of ATL-1103 cleared to continue by DSMB

Treatment begins in Bone Therapeutics' phase IIb/III study of PREOB in non-union fractures

FibroGen reports interim data from phase II FG-3019 study

FDA grants priority review to Dalvance NDA

GSK plans phase II study of GSK-2586184 for ulcerative colitis

Aurora kinase A inhibitor synergized with taxanes for the treatment of drug-resistant cancers

A team of researchers at Ariad Pharmaceuticals discloses novel EGFR inhibitors for cancer

Merck & Co. synthesizes new CGRP receptor antagonists for migraine

New O-GlcNAcase inhibitors discovered by Alectos Therapeutics and Merck & Co.

Novel ALK tyrosine kinase receptor inhibitors reported

New SGLT1 inhibitors for diabetes patented by Eli Lilly

Lycera and Merck & Co. divulge novel nuclear receptor ROR-gamma inhibitors

Eisai seeks Japanese approval of Pariet for new indication, new formulation

FDA approves Velphoro to treat hyperphosphatemia in patients with CKD on dialysis

FDA approves Varithena for the treatment of patients with incompetent veins

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...